Loading
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
Previous close
$0.2894
+$0.0009 · +0.31%
After-hours
$0.2947
+$0.0053 · +1.83%
Oct 7, 7:57 PM ET
Regular session · ET · Market data may be delayed.
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
Day range
Current $0.2894
52-week range
Current $0.2894
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
27
Expensive
Sentiment
43
Mixed
Risk
93
Extreme Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
Day range
Current $0.2894
52-week range
Current $0.2894
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.49M USD | 3.95M USD | — | 81.53K USD | 385.5K USD |
| Cost of goods sold | 18.12M USD | 95.37K USD | 20.72M USD | 9.12M USD | 15.55M USD |
| Gross profit | −15.63M USD | 3.86M USD | −20.72M USD | −9.04M USD | −15.17M USD |
| Research and development | 18.12M USD | 23.71M USD | 20.72M USD | 9.12M USD | 15.55M USD |
| Selling, general, and administrative | 6.01M USD | 5.39M USD | 5.95M USD | 4.99M USD | 3.58M USD |
| Operating expenses | 6.01M USD | 29M USD | 6.02M USD | 4.99M USD | 3.58M USD |
| Interest income | 174.28K USD | 173.36K USD | 776.18K USD | 7.44K USD | 4.74K USD |
| Interest expense | — | 21.38K USD | — | — | 1.29K USD |
| Depreciation and amortization | 68.76K USD | 95.37K USD | 74.17K USD | 56.28K USD | 38.52K USD |
| Operating income | −21.64M USD | −25.14M USD | −26.74M USD | −14.03M USD | −18.75M USD |
| Net income | −21.46M USD | −24.99M USD | −25.97M USD | −14.02M USD | −18.57M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$100
34454.25% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 12, 2026 | 1:25 | — | — |
Stock split | Jan 31, 2024 | 1:15 | — | — |
Stock split | Sep 25, 2020 | 1:20 | — | — |
Stock split | Jan 24, 2020 | 1:2,000 | — | — |
Stock split | May 2, 2019 | 1:500 | — | — |
Stock split | Apr 28, 2010 | 1:50 | — | — |
Effective Jan 12, 2026
1:25
Effective Jan 31, 2024
1:15
Effective Sep 25, 2020
1:20
Effective Jan 24, 2020
1:2,000
Effective May 2, 2019
1:500
Effective Apr 28, 2010
1:50
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
